Benralizumab is prescribed for:
- Severe eosinophilic asthma
- Add-on maintenance treatment
- Reducing oral corticosteroid use
- Respiratory severe disease management
Targets eosinophils through IL-5 receptor binding.
Generic Name: Benralizumab
Brand Names: Fasenra
Benralizumab is a biologic that depletes eosinophils for severe eosinophilic asthma.
Benralizumab is prescribed for:
Targets eosinophils through IL-5 receptor binding.
Common side effects:
Serious side effects:
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor on eosinophils, causing rapid and near-complete eosinophil depletion.
Unlike other anti-IL-5 biologics, benralizumab causes direct eosinophil cell death through antibody-dependent cellular cytotoxicity (ADCC).
After initial doses, administered every 8 weeks (less frequent than some biologics).
For details, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Asthma, a chronic lung disease, causes airway inflammation and narrowing, resulting in wheezing, coughing, and shortness of breath, triggered by allergens, irritants, infections, or stress.
ADHD is a neurodevelopmental disorder marked by inattention, hyperactivity, and/or impulsivity, stemming from complex interactions between genetics, brain differences, and environmental factors, not poor parenting.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Benralizumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.